HGHaoyue Guo

Haoyue Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haoyue Guo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Caicun Zhou

    Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

    1 shared publication
  • Chao Zhao

    Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Shanghai, China

    1 shared publication
  • Fang Dai

    Department of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, PR China

    1 shared publication
  • Hao Wang

    Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China

    1 shared publication
  • Hui Lu

    State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication
  • Huoqiang Wang

    Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Multimodal multitask deep learning for grading management system in non-small cell lung cancer

    by Xinyue Liu, Fang Dai, Jiawei Dai, Huoqiang Wang, Qiang Li, Yaokai Wen, Haoyue Guo, Lishu Zhao, Hao Wang, Kandi Xu, et al.

    Accurate histologic subtyping, tumor node metastasis classification (TNM) staging and prognostic assessment are central to clinical management of non-small cell lung cancer (NSCLC), but remain challenging because of tumor heterogeneity, limited biomarker performance and diagnostic uncertainty. Here we show that a multimodal, multi-task deep learning scoring system (MM-DLS), integrating pretreatment PET/CT images with clinical variables, enables non-invasive prediction of NSCLC subtype, stage and survival risk. We develop and validate MM-DLS in 4,164 patients from multiple centres. In the external validation cohort, MM-DLS achieves area under the receiver operating characteristic curve values of 0.86 for histologic subtype classification and 0.86, 0.86, and 0.88 for stages I-II, III, and IV, respectively. The model also shows consistently strong discrimination for 1-, 3-, and 5-year survival across treatment regimens. These results indicate that MM-DLS provides an integrated framework for subtype prediction, staging, and prognostic stratification in NSCLC.


  • Open Access

    Lipid Metabolism Related Gene ACSL3 as a Biomarker for Predicting Immunotherapy Outcomes in Lung Adenocarcinoma

    by Taiping He, Jinhan Hu, Haoyue Guo, Meng Diao, Yuanyuan Wang, Yuhan Wu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou

    Investigate the role of lipid metabolism in the tumor immune microenvironment (TIME) of lung adenocarcinoma (LUAD) and identify vital lipid metabolism-related genes (LMRGs) that contribute to immunotherapy outcomes. 1130 LUAD patients were acquired utilizing public databases. Multiple algorithms were used to analyze the contribution of lipid metabolism in TIME. Importantly, cell lines, clinical samples (52 patients in surgery cohort and 36 in immunotherapy cohort), animal models, RNA-seq, experiments in protein and mRNA levels were conducted for identifying and validating key biomarker in LUAD immunotherapy. A prognostic signature comprising 33 LMRGs was developed and validated as an effective predictor of prognosis and TIME, with a C-index of 0.766 (95% CI: 0.729-0.804). Additionally, we identified Acyl-CoA Synthetase Long Chain Family Member 3 (ACSL3) as a potential biomarker for immunotherapy prognosis. The expression of ACSL3 was verified in 88 clinical tissues from LUAD patients, which indicated that elevated ACSL3 expression was correlated with worse progression-free survival (PFS) (p<0.001) and overall survival (OS) (p=0.008). Subsequent experiments revealed that knockdown of ACSL3 in vivo enhanced the efficacy of immunotherapy, potentially through increasing interferon α secretion, as indicated by Bulk RNA-seq and ELISA analysis, thereby promoting the infiltration of anti-tumor immune cells. The study established a model that accurately predicts immunotherapy response, prognosis, and TIME dynamics in LUAD patients. Notably, the pivotal role of ACSL3 in driving tumor progression and immune evasion was uncovered, offering novel insights into the optimization of immunotherapy strategies for LUAD.